Crescent Biopharma jumps after cancer drug partnership
ReutersDec 4, 2025 12:24 PM
Shares of drugmaker Crescent Biopharma CBIO.O rise 36.5% to $18.30 premarket
Co says it has formed an exclusive partnership with China's Kelun-Biotech to develop and market new cancer treatments
Co is also raising $185 million from investors to fund clinical trials - CBIO
Says deal gives Kelun-Biotech rights to co's experimental drug CR-001 in Greater China
CBIO's CR-001 aims to boost immune response and block blood supply to tumors; SKB105 targets solid tumors, co says
Both firms plan to test drugs alone and in combination; human trials for 3 drugs set for 2026, co says
Up to last close, stock was down ~46% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Why the Future of AI Compute is in Space: 2026 Investment Guide
Explore 2026 investment roadmap for Space Data Centers as AI computing breaks free from terrestrial energy and cooling constraints. Discover how key players like SpaceX, Rocket Lab, and Northrop Grumman are building the "Space Silicon Valley" from orbital infrastructure to real-time AI applications.TradingKey
21 hours ago
TradingKey 2025 Markets Recap & Outlook | Wall Street Bullish on 2026: S&P 500 Forecast at 8,000 with AI Gains and Cyclical Stocks Soaring
TradingKey - As 2025 draws to a close, the U.S. stock market has delivered a series of exciting and astonishing moments. As 2026 approaches, major Wall Street banks remain confident about the outlook for U.S. equities, with an average forecast for the S&P 500 index reaching 7,500 points.TradingKey
Wed, Dec 24
Ripple Price Prediction: Why Is XRP Price Falling? Can It Rise to $10 in the Future?
XRP has weakened this year due to profit-taking, capital outflows, and its correlation with Bitcoin. Despite support from potential spot ETFs and positive regulatory developments, significant market divergence, liquidity uncertainty, and macroeconomic uncertainty remain high. XRP's price is likely tTradingKey
Wed, Dec 24
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital baTradingKey
Fri, Dec 19
Tradingkey
